Key statistics
As of last trade Zai Lab Ltd (ZLAB:NMQ) traded at 25.82, -29.45% below its 52-week high of 36.60, set on Oct 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.34 |
---|---|
High | 26.55 |
Low | 25.33 |
Bid | 25.81 |
Offer | 25.86 |
Previous close | 26.23 |
Average volume | 1.71m |
---|---|
Shares outstanding | 108.63m |
Free float | 105.35m |
P/E (TTM) | -- |
Market cap | 2.90bn USD |
EPS (TTM) | -2.78 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 19:40 GMT.
More ▼
Press releases
- Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
- Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
- Zai Lab Announces Pricing of Public Offering of American Depositary Shares
- Zai Lab Announces Proposed Public Offering of American Depositary Shares
- Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
- Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
- Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
- ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
- Zai Lab Announces Participation in November and December Investor Conferences
- Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
More ▼